

Expert Second Opinion: Investigators Discuss the Optimal Management of HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. What is the estimated prevalence of HER2 mutations in colorectal cancer?**
  - a. 20% to 25%
  - b. 8% to 10%
  - c. 1% to 2%**
- 2. Which of the following classes of therapeutic agents is not recommended for the treatment of HER2-positive colorectal cancer?**
  - a. PD-L1 inhibitors
  - b. EGFR tyrosine kinase inhibitors**
  - c. TROP2 antibody drug conjugates
- 3. The ongoing Phase III MOUNTAINEER-03 trial is evaluating the addition of HER2-targeted therapy to chemotherapy for patients with HER2-positive colorectal cancer in what setting?**
  - a. As adjuvant therapy for Stage III disease
  - b. As first-line therapy**
  - c. As maintenance therapy after complete response to first-line therapy
  - d. As second-line therapy
- 4. The Phase III HERIZON-GEA-01 trial reported which of the following outcomes with the first-line combination of zanidatamab with tislelizumab and chemotherapy compared to the control arm of trastuzumab with chemotherapy for patients with HER2-positive metastatic gastroesophageal cancer?**
  - a. A statistically significant overall survival benefit**
  - b. An equivalent overall survival benefit
  - c. An inferior overall survival outcome